Jazz Pharma Plc (JAZZ) 150.53 $JAZZ Covered Call reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Jazz Pharma Plc (JAZZ) 150.53 $JAZZ

Covered Call reports for Marathon Oil Corporation, Amazon.com, Jazz Pharmaceuticals, Kellogg Company and Nike include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, JAZZ, K, MRO, and NKE.
AMZN: 767.74 (+8.93), NKE: 55.41 (-0.09), JAZZ: 150.53 (-0.44), MRO: 12.92 (-0.72), K: 82.37 (-0.34)

Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
PR Newswire Europe - Thu Jul 28, 3:06PM CDT
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration demonstrates Jazz Pharmaceuticals' focus on identifying innovative technologies that may lead to the development of important therapeutic options for patients with hematological malignancies.
JAZZ: 150.53 (-0.44), PFNX: 8.60 (+0.53)

Look for Shares of Jazz Pharmaceuticals to Potentially Rebound after Yesterday's 1.06% Sell Off
Comtex SmarTrend(R) - Mon Jul 25, 4:23PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $140.30 to a high of $142.02. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.79 on volume of 226,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)

Jazz Pharmaceuticals to Report 2016 Second Quarter Financial Results on August 9, 2016
PR Newswire Europe - Mon Jul 25, 3:06PM CDT
Jazz Pharmaceuticals plc today announced that it will report its 2016 second quarter financial results on Tuesday, August 9, 2016, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2016 financial results and provide a business and financial update.
JAZZ: 150.53 (-0.44)

Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc.
PR Newswire Europe - Tue Jul 12, 12:50AM CDT
Jazz Pharmaceuticals plc today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals, Inc. at $30.25 per share, net to the seller in cash, without interest (less any required withholding taxes). The tender offer is being effected by Jazz Pharmaceuticals' indirect wholly-owned subsidiary, Plex Merger Sub, Inc.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)

After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)

Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)

Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 61.06 (+0.46), JAZZ: 150.53 (-0.44), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38)

Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 150.53 (-0.44)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company" (Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz".
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.43 (+0.15), JAZZ: 150.53 (-0.44), GRFS: 16.76 (-0.18), PBYI: 49.04 (-0.85)

Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company" in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)

Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 150.53 (-0.44)

Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 150.53 (-0.44)

CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" (NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)

Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.24 (unch), GXP: 29.70 (-0.08), WR: 55.42 (-0.15), MDT: 88.06 (+0.43), JAZZ: 150.53 (-0.44)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 94

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 96

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 142

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 154

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 141

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 133

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 55

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet

Updated Category News Views 44

Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 25

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 65

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading

Top 5 Most Recently Viewed Articles

Rogers Communications Adjusts Revenue Forecast After Sports Deal

Updated Category News Views 203

Rogers Communications Expands Outlook Following Sports Acquisition Rogers Communications, Inc. (NYSE: RCI) has made headlines after raising its full-year service revenue guidance following a solid earnings performance. Despite a slight decline in stock value, investors reacted positively to the company's updated expectations after their second-quarter financial report....

Continue Reading
Tata Communications Expands AI Capabilities with New Acquisition

Updated Category News Views 188

Tata Communications Enhances AI Capabilities Tata Communications, a prominent player in the global communications technology landscape, has recently taken a significant step in advancing its AI capabilities. The company announced its acquisition of a 51% stake in Commotion Inc., an innovative AI-native Enterprise SaaS platform. This acquisition highlights Tata...

Continue Reading
Taboola to Announce Q3 2024 Earnings: Conference Call Details

Updated Category News Views 152

Taboola Prepares for Third Quarter 2024 Financial Announcement Taboola, renowned for its dynamic recommendation platform, is making headlines as it gears up to release its financial results for the third quarter of 2024. This exciting event is scheduled for a Thursday morning before the market opens, paving the way for insights into the company's performance. Date and...

Continue Reading
Aker Horizons ASA Holds Key Extraordinary General Meeting

Updated Category News Views 126

Aker Horizons ASA Holds Key Extraordinary General Meeting In a significant step for Aker Horizons ASA, the company's extraordinary general meeting was successfully conducted. The meeting, held digitally, emphasized the importance of engaging stakeholders through innovative online participation. This format makes it easier for shareholders to be involved, regardless of...

Continue Reading
Energizer® Portable Power Expands European Availability Now

Updated Category News Views 147

Energizer® Portable Power Expands European Availability Energizer, a name synonymous with reliable power solutions, has taken a bold step forward with the expansion of its portable power ecosystem across Europe. This strategic move by TennRich International Corp. signals a commitment to enhancing modern lifestyles, perfectly aligning with the needs of consumers at home,...

Continue Reading